- Biogen’s mixed Alzheimer’s data; Two new startups launch; and moreWelcome back to another edition of Endpoints Weekly! We hope you all have been staying safe indoors as the Canadian wildfires blanketed much of the US Northeast this week. Hopefully things calm dow…Endpoints · 7d ago↗ source
- ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsAfter Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.Fierce Biotech · 7d ago↗ source
- Opinion: STAT readers on the value of primary care, obesity as a disease, and more“The real opportunity is to move beyond policies and narratives that pit specialties against one another,” presidents of the AAFP, ACP, and AAP write.